P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Leukemia

Volumn 18, Issue 3, 2004, Pages 401-408

  Illmer, T ^a   Schaich, M ^a   Platzbecker, U ^a   Freiberg Richter, J ^a   Oelschlagel U ^a   von Bonin, M ^a   Pursche, S ^a   Bergemann, T ^a   Ehninger, G ^a   Schleyer, E ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bcr Abl tyrosine kinase; CML; HPLC; Imatinib; Multidrug resistance

Indexed keywords

BCR ABL PROTEIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN TYROSINE KINASE; RHODAMINE; VERAPAMIL; ANTINEOPLASTIC AGENT; CRK LIKE PROTEIN; CYCLOSPORIN; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CASE REPORT; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG TRANSPORT; EDEMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIVER TOXICITY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; CELL DIVISION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; NUCLEAR PROTEINS; P-GLYCOPROTEIN; PIPERAZINES; PYRIMIDINES; RHODAMINES;

EID: 1542713480     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403257     Document Type: Article

References (27)

1. Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol 2002; 119: 15-24.
2. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-1942.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
5. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-1766.
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
7. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359: 487-491.
8. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843.
9. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99: 10700-10705.
10. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-475.
11. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
12. Gottesman MM, Fojo T, Bates SE. Multidiug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
13. Giles FJ, Kantarjian HM, Cortes J, Thomas DA, Talpaz M, Manshouri T et al. Multidrug resistance protein expression in chronic myeloid leukemia: Associations and significance. Cancer 1999; 86: 805-813.
14. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955-4962.
15. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995; 9: 1549-1555.
16. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 2262-2271.
17. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002; 62: 188-199.
18. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001; 98: 3212-3220.
19. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85.
20. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 2002; 359: 481-486.
21. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664-672.
22. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
23. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996; 10: 937-942.
24. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
25. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D et al. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 2002; 100: 1910-1912.
26. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: A novel mechanism for MDR-1 gene activation. J Clin Invest 1997; 99: 1947-1957.
27. Brummendorf TH, Ersoz I, Hartmann U, Bartolovic K, Balabanov S, Wahl A et al. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. Blood 2003; 101: 375-376.